...
首页> 外文期刊>Biochimica et biophysica acta. Molecular basis of disease: BBA >Epigenetic landscape in PPAR gamma 2 in the enhancement of adipogenesis of mouse osteoporotic bone marrow stromal cell
【24h】

Epigenetic landscape in PPAR gamma 2 in the enhancement of adipogenesis of mouse osteoporotic bone marrow stromal cell

机译:PPARγ2中的表观遗传学景观在增强小鼠骨质疏松性骨髓基质细胞成脂中的作用

获取原文
获取原文并翻译 | 示例

摘要

Osteoporosis is one of the most prevalent skeletal system diseases; yet, its pathophysiological mechanisms remain elusive. Adipocytes accumulate remarkably in the bone marrow of osteoporotic patients. The potential processes and molecular mechanisms underlying adipogenesis in osteoporotic BMSCs have attracted significant attention as adipocytes and osteoblasts share common precursor cells. Some environmental factors influence bone mass through epigenetic mechanisms; however, the role of epigenetic modifications in osteoporosis is just beginning to be investigated, and there is still little data regarding their involvement In the current study, we investigated how epigenetic modifications, including DNA methylation and histone modifications, lead to adipogenesis in the bone marrow during osteoporosis. A glucocorticoid-induced osteoporosis (GIO) mouse model was established, and BMSCs were isolated from the bone marrow. Compared with normal BMSCs, osteoporotic BMSCs had significantly increased adipogenesis potential and decreased osteogenesis potential. In osteoporotic BMSCs, PPAR gamma 2 regulatory region DNA hypo-methylation, histone 3 and 4 hyper-acetylation and H3K9 hypodi-methylation were observed. These epigenetic modifications were involved not only in PPAR gamma 2 expression but also in osteoporotic BMSC adipogenic differentiation potential. We also found that Wnt/beta-catenin signal played an important role in the establishment and maintenance of epigenetic modifications at PPAR-gamma 2 promoter in osteoporotic BMSCs. Finally, we inhibited adipogenesis and rescued osteogenesis of osteoporotic BMSCs by modulating those epigenetic modifications. Our study provides a deeper insight into the pathophysiology of osteoporosis and identifies PPAR gamma 2 as a new target for osteoporosis therapy based on epigenetic mechanisms. (C) 2015 Elsevier B.V. All rights reserved.
机译:骨质疏松症是最普遍的骨骼系统疾病之一;然而,其病理生理机制仍然难以捉摸。脂肪细胞在骨质疏松症患者的骨髓中大量积累。随着脂肪细胞和成骨细胞共享共同的前体细胞,骨质疏松BMSCs中脂肪形成的潜在过程和分子机制引起了广泛的关注。一些环境因素通过表观遗传机制影响骨量。然而,表观遗传修饰在骨质疏松症中的作用才刚刚开始被研究,关于它们参与程度的数据仍然很少。在本研究中,我们研究了表观遗传修饰如何导致DNA甲基化和组蛋白修饰导致骨髓成脂在骨质疏松症期间。建立了糖皮质激素诱导的骨质疏松症(GIO)小鼠模型,并从骨髓中分离了BMSC。与正常骨髓间充质干细胞相比,骨质疏松的骨髓间充质干细胞具有显着增加的成脂潜能和成骨潜能。在骨质疏松的骨髓间充质干细胞中,观察到PPARγ2调节区DNA低甲基化,组蛋白3和4过度乙酰化以及H3K9低二甲基化。这些表观遗传修饰不仅与PPARγ2表达有关,而且与骨质疏松BMSC成脂分化潜能有关。我们还发现Wnt /β-catenin信号在骨质疏松BMSCs中PPAR-γ2启动子的表观遗传修饰的建立和维持中起着重要作用。最后,我们通过调节表观遗传修饰来抑制骨质疏松BMSC的脂肪形成并挽救其成骨作用。我们的研究为骨质疏松症的病理生理学提供了更深入的见解,并基于表观遗传机制将PPAR gamma 2鉴定为骨质疏松症治疗的新靶标。 (C)2015 Elsevier B.V.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号